Last reviewed · How we verify
Clopirin 2
Clopirin 2 is an antiplatelet agent that inhibits platelet aggregation to reduce thrombotic events.
Clopirin 2 is an antiplatelet agent that inhibits platelet aggregation to reduce thrombotic events. Used for Prevention of atherothrombotic events in patients with acute coronary syndrome, Secondary prevention of myocardial infarction and stroke.
At a glance
| Generic name | Clopirin 2 |
|---|---|
| Sponsor | Jeil Pharmaceutical Co., Ltd. |
| Drug class | P2Y12 receptor antagonist / Antiplatelet agent |
| Target | P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Clopirin 2 is a clopidogrel-based antiplatelet medication that works by irreversibly inhibiting platelet P2Y12 adenosine diphosphate receptors, preventing platelet activation and aggregation. This mechanism reduces the formation of blood clots and is used to prevent cardiovascular and cerebrovascular thrombotic events in patients at risk.
Approved indications
- Prevention of atherothrombotic events in patients with acute coronary syndrome
- Secondary prevention of myocardial infarction and stroke
Common side effects
- Bleeding
- Dyspepsia
- Rash
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |